Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies

Trial Profile

A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; Irinotecan (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Endometrial cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Athenex
  • Most Recent Events

    • 15 Oct 2019 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
    • 15 Oct 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
    • 04 Jun 2019 Results assessing maximum tolerated dose and dose limiting toxicities of irinotecan in combination with HM30181A presented at the 55th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top